Protalix BioTherapeutics
PLX
PLX
37 hedge funds and large institutions have $58.4M invested in Protalix BioTherapeutics in 2015 Q1 according to their latest regulatory filings, with 2 funds opening new positions, 7 increasing their positions, 16 reducing their positions, and 9 closing their positions.
New
Increased
Maintained
Reduced
Closed
less ownership
Funds ownership: →
less capital invested
Capital invested by funds: $ → $
less funds holding
Funds holding: →
less repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
60% less call options, than puts
Call options by funds: $43K | Put options by funds: $108K
78% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 9
Holders
37
Holding in Top 10
–
Calls
$43K
Puts
$108K
Top Buyers
| 1 | +$1.01M | |
| 2 | +$168K | |
| 3 | +$92.5K | |
| 4 |
Simplex Trading
Chicago,
Illinois
|
+$39.6K |
| 5 |
NCCM
Nine Chapters Capital Management
Short Hills,
New Jersey
|
+$27K |
Top Sellers
| 1 | -$3.68M | |
| 2 | -$1.55M | |
| 3 | -$525K | |
| 4 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
-$392K |
| 5 |
DCM
DAFNA Capital Management
Los Angeles,
California
|
-$273K |